TG Therapeutics (TGTX) Sees Price Target Drop from JPMorgan

TG Therapeutics Inc. (NASDAQ:TGTX) is one of the 13 Best Revenue Growth Stocks to Buy Right Now. On February 2, JPMorgan analyst Brian Cheng reduced the price target on TG Therapeutics (NASDAQ:TGTX) to $46 from $49 while maintaining the Overweight rating on the shares. The investment bank had recently updated the model on the company. TG Therapeutics presented its trial results on February 6 at a medical forum in San Diego, California. The presentation focused on the results of its Briumvi treatment for relapsing multiple sclerosis in adults. Earlier, in mid-January, H.C. Wainwright analyst Emily Bodnar gave a Buy rating on the stock, citing the company’s strong commercial momentum and anticipated clinical catalysts in 2026. These include results for consolidated IV dosing and self-administered subcutaneous formulation for Briumvi, which could boost its market share against competing therapies. On January 29, TD Cowen analyst Tara Bancroft reiterated a Buy rating on TG Therapeutics and set a $50 price target. While we acknowledge the potential of TGTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 12 Best Software Infrastructure Stocks to Buy According to Hedge Funds and Cathie Wood’s Stock Portfolio: Top 10 Stocks to Buy. Disclosure: None. This article is originally published at Insider Monkey.